Serotonin-selective reuptake inhibitors and nonsteroidal anti-inflammatory drugs-important considerations of adverse interactions especially for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 403-405

  Theoharides, Theoharis C ^a,b   Asadi, Shahrzad ^a   Weng, Zuyi ^a,b   Zhang, Bodi ^a  

^a Molecular Immunopharmacology and Drug Discovery Laboratory   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CURCUMIN; DESIPRAMINE; EPIGALLOCATECHIN; GAMMA INTERFERON; IBUPROFEN; LUTEOLIN; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR;

CHRONIC FATIGUE SYNDROME; EDITORIAL; ENCEPHALOMYELITIS; GASTROINTESTINAL HEMORRHAGE; NONHUMAN; PRIORITY JOURNAL; RISK; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; DRUG INTERACTIONS; FATIGUE SYNDROME, CHRONIC; GASTROINTESTINAL HEMORRHAGE; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 79960604750     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318225848c     Document Type: Editorial

References (39)

1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953-959. (Pubitemid 24370860)
2. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry. 2003;160:221-236. (Pubitemid 41110447)
3. Jason LA, Corradi K, Torres-Harding S, et al. Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev. 2005;15:29-58. (Pubitemid 40576934)
4. Santhouse AM, Hotopf M, David AS. Chronic fatigue syndrome. BMJ. 2010;340:c738.
5. Avellaneda FA, Perez MA, Izquierdo MM, et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry. 2009;9(Suppl 1):S1.
6. Van HB, Kempke S, Luyten P. Psychiatric aspects of chronic fatigue syndrome and fibromyalgia. Curr Psychiatry Rep. 2010;12:208-214.
7. Rimes KA, Chalder T. Treatments for chronic fatigue syndrome. Occup Med (Lond). 2005;55:32-39. (Pubitemid 40310101)
8. Pae CU, Marks DM, Patkar AA, et al. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10:1561-1570.
9. Mease PJ. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med. 2009;122:S44-S55.
10. Staud R. Pharmacological treatment of fibromyalgia syndrome: new developments. Drugs. 2010;70:1-14.
11. Pae CU, Marks DM, Patkar AA, et al. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10:1561-1570.
12. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301:198-209.
13. Hameroff SR, Cork RC, Weiss JL, et al. Doxepin effects on chronic pain and depression: a controlled study. Clin J Pain. 1985;1:171-176. (Pubitemid 16180958)
14. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2011. [Epub ahead of print].
15. Clemons A, Vasiadi M, Kempuraj D, et al. Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. J Clin Psychopharmacol. 2011;31:385-387.
16. Theoharides TC, Papaliodis D, Tagen M, et al. Chronic fatigue syndrome, mast cells, and tricyclic antidepressants. J Clin Psychopharmacol. 2005;25:515-520. (Pubitemid 41669041)
17. Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71:1565-1575.
18. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104:1475-1482.
19. Bell JS, Taipale HT, Soini H, et al. Concomitant use of SSRIs, NSAIDs/aspirin and gastroprotective drugs among residents of long-term care facilities: a medical record reviewfs. Clin Drug Investig. 2011;31:337-344.
20. de Jong JC, van den Berg PB, Tobi H, et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2003;55:591-595. (Pubitemid 36783201)
21. Weinrieb RM, Auriacombe M, Lynch KG, et al. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf. 2005;4:337-344. (Pubitemid 40867343)
22. Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006;26:1307-1313. (Pubitemid 44306891)
23. Helin-Salmivaara A, Huttunen T, Gronroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol. 2007;63:403-408. (Pubitemid 46399132)
24. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27:31-40. (Pubitemid 350212624)
25. Warner-Schmidt JL, Vanover KE, Chen EY, et al. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA. 2011;108(22):9262-9267.
26. Theoharides TC, Weinkauf C, Conti P. Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol. 2004;24:577-581. (Pubitemid 39518651)
27. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry. 2009;22:32-36.
28. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.
29. Muller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs. 2010;11:31-42.
30. Kempuraj D, Madhappan B, Christodoulou S, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol. 2005;145:934-944. (Pubitemid 41129015)
31. Kempuraj D, Tagen M, Iliopoulou BP, et al. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol. 2008;155:1076-1080.
32. Jang SW, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA. 2010;107:2687-2692.
33. Jang S, Dilger RN, Johnson RW. Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J Nutr. 2010;140:1892-1898.
34. Chen HQ, Jin ZY, Wang XJ, et al. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett. 2008;448:175-179.
35. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev. 2000;52:673-751.
36. Kuo YH, Tsai WJ, Loke SH, et al. Astragalus membranaceus flavonoids (AMF) ameliorate chronic fatigue syndrome induced by food intake restriction plus forced swimming. J Ethnopharmacol. 2009;122:28-34.
37. Singh A, Naidu PS, Gupta S, et al. Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome. J Med Food. 2002;5:211-220. (Pubitemid 36331634)
38. Sachdeva AK, Kuhad A, Tiwari V, et al. Epigallocatechin gallate ameliorates chronic fatigue syndrome in mice: behavioral and biochemical evidence. Behav Brain Res. 2009;205:414-420.
39. Gupta A, Vij G, Sharma S, et al. Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. Immunobiology. 2009;214:33-39.